Question:
What documentation elements are necessary to support NTAP eligibility and PCS accuracy when reporting use of the Agent Paclitaxel-Coated Balloon Catheter?
Answer:
The Agent Paclitaxel-Coated Balloon Catheter, approved for NTAP has a maximum add-on of $4,013.75. This device is designed for the treatment of in-stent restenosis, providing targeted paclitaxel delivery without a permanent implant. It serves as an alternative strategy when placing a new stent is not ideal. Because the device delivers a therapeutic agent, NTAP reporting relies on XW0-series PCS codes, depending on the anatomical site and approach documented. Note that this is also a Breakthrough Device, and CMS is supporting its adoption through NTAP due to its potential to improve ISR outcomes. From a documentation standpoint, ensure the operative note clearly identifies its use, the treated vessel, and the rationale for selecting a drug-coated balloon over repeat stenting. These details ensure both PCS accuracy and NTAP eligibility.
This question was answered in our annual Cardiology Reimbursement & Compliance Update webcast. For more hot topics relating to cardiology services, please visit our store or call us at 1.800.252.1578, ext. 2.
